BioSpace News Archive

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, presented results from the Phase 1 study of AT-527 in healthy volunteers at the 28th Annual Conference on Retroviruses and Opportunistic Infections in a Science Spotlight presentation.

The findings reported on a secondary objective to reduce time to negativity of infectious SARS-CoV-2 virus isolation from nasopharyngeal swabs from participants with symptomatic COVID-19

Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Mayne Pharma announced new data showing treatment with NEXTSTELLIS®,1 a novel, investigational combined oral contraceptive containing drospirenone and estetrol, resulted in limited changes in endocrine markers, including lower increases in hormone binding globulins, compared with COCs based on ethinyl-estradiol, the synthetic estrogen used in all but one of the marketed COCs.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced a supply agreement with the Government of The Philippines for 13 million doses of the COVID-19 Vaccine Moderna.